Nov 12, 2024 Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
Sep 16, 2024 Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024
Sep 04, 2024 Checkpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
Aug 12, 2024 Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Updates
Jul 25, 2024 Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma
Jul 02, 2024 Checkpoint Therapeutics Announces $12 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Jul 02, 2024 Checkpoint Therapeutics Announces Biologics License Application Resubmission for Cosibelimab
Jun 24, 2024 Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission
May 13, 2024 Checkpoint Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference